Heart failure in a district general hospital: Are target doses of beta-blockers realistic?

QJM: An International Journal of Medicine

Volumn 97, Issue 3, 2004, Pages 133-139

  Mehta, P A ^a   McDonagh, S ^b   Poole Wilson, P A ^a   Grocott Mason, R ^b   Dubrey, S W ^b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b HILLINGDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIGOXIN; LOOP DIURETIC AGENT; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG TOLERABILITY; DRY EYE; DYSPNEA; FEMALE; GENERAL HOSPITAL; HEART FAILURE; HEART RATE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; NURSE; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PATIENT SELECTION; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT FAILURE; WORKING TIME;

EID: 1542709231     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/hch023     Document Type: Article

References (22)

1. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, et al. The epidemiology of heart failure. Eur Heart J 1997; 18:208-15..
2. Petersen S, Rayner M. Coronary heart disease statistics: heart failure supplement. London: British Heart Foundation, 2002.
3. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334:1349-55.
4. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomised trial. Lancet 1999; 353:9-13.
5. MERIT-HF Study Group. Effects of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA 2000; 283:1295-302.
6. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure (COPERNICUS). N Engl J Med 2001; 344:1651-8.
7. Davies MK, Hobbs FDR, Davis RC, et al. Prevalence of left ventricular systolic dysfunction and heart failure in the echocardiographic Heart of England screening study. Lancet 2001; 358:439-44.
8. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress and practice. Prog Cardiovasc Dis 1998; 41(Suppl.):39-52.
9. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 2003; 362:7-13.
10. Mahmoudi M, McDonagh S, Poole-Wilson PA, Dubrey SW. Obstacles to the initiation of β Blockers for heart failure in a specialized clinic within a district general hospital. Heart 2003; 89:442-4.
11. Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant 2002; 21:1290-5.
12. Gattis WA, O'Connor CM, Leimberger JD, Felker GM, Adams KF, Gheorghiade M. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. Am J Cardiol 2003; 91:169-74.
13. Bellotti P, Bardano LP, Acquarone N, et al. Specialty related differences in the epidemiology, clinical profile, management and outcome of patients hospitalized for heart failure. Eur Heart J 2001; 22:596-604.
14. Australia/New Zealand Heart Failure research Collaborative Group. Randomised placebo controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349:375-80.
15. Krum H, Ninio D, MacDonald P. Baseline predictors of tolerability to carvedilol in patients with chronic heart failure. Heart 2000; 84:615-19.
16. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996; 94:2807-16.
17. Wickstrand JCM, Hjalmarson A, Waagstein F, et al. Achieved metoprolol CR/XL dose and clinical outcomes, analysis of the experience in MERIT HF. Circulation 2001; 104:11-753.
18. Maggioni AP, Sinagra G, Opasich C, Geraci E, Gorini M, Gronda E, Lucci D, Tognoni G, Balli E, Tavazzi L. Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. Heart 2003; 89:299-305.
19. Cowie MR, Wood DA, Coats AJS, et al. Incidence and aetiology of heart failure: A population study. Eur Heart J 1999; 20:421-8.
20. British National Formulary, No. 45. March 2003.
21. Najib MM, Goldberg Arnold RJ, Kaniecki DJ, Pettit KG, Roth D, Antell L, Xuan J. Medical resource use and costs of congestive heart failure after carvedilol use. Heart Dis 2002; 4:70-7.
22. Gregory D, Udelson JE, Konstam MA. Economic impact of beta blockade in heart failure. Am J Med 2001; 110(Suppl. 7A):74-80S.